1.Kuritzkes DR. HIV–1 subtype as a determinant of disease progression. J Infect Dis 2008;197: 638–9.
2.Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV–1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV–1 loads. J Infect Dis 2007;195: 1177–80.
3.Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire-Mangen F, Makumbi FE, et al. HIV–1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010;54: 180–4.
4.Collaborative Group on AIDS Incubation and HIV Survival, including the CASCADE EU Concerted Action. Time from HIV–1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000;355: 1131–7.
5.Nelson KE, Costello C, Suriyanon V, Sennun S, Duerr A. Survival of blood donors and their spouses with HIV–1 subtype E (CRF01 A_E) infection in northern Thailand, 1992–2007. AIDS 2007;21 Suppl 6: S47–54.
6.Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE. The natural history of HIV–1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 2007;21 Suppl 6: S39–46.
7.Li Y, Han Y, Xie J, Gu L, Li W, Wang H, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS 2014;28: 521–30.
8.Cui H, Geng W, Sun H, Han X, An M, Jiang Y, et al. Rapid CD4+ T-cell decline is associated with coreceptor switch among MSM primarily infected with HIV–1 CRF01_AE in Northeast China. AIDS 2019;33: 13–22.
9.Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010;24: 2803–8.
10.Avettand-Fenoel V, Bouteloup V, Melard A, Fagard C, Chaix ML, Leclercq P, et al. Higher HIV–1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123—ETOILE). J Antimicrob Chemother 2010;65: 2212–4.
11.Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD–1)-expressing CD4+ T cells. J Infect Dis 2013;208: 50–6.
12.Cockerham LR, Siliciano JD, Sinclair E, O’Doherty U, Palmer S, Yukl SA, et al. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One 2014;9: e110731.
13.Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 2016;2: 43–8.
14.Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total HIV–1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin Microbiol Rev 2016;29: 859–80.
15.Jumare J, Sunshine S, Ahmed H, El-Kamary SS, Magder L, Hungerford L, et al. Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. J Neurovirol 2017;23: 474–82.
16.Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard PM, et al. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 2015;29: 2003–7.
17.Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016;30: 343–53.
18.Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, et al. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China. Chin Med J (Engl) 2014;127: 59–65.
19.Hsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, et al. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016;30: 1935–42.
20.Guo F, Cheng X, Hsieh E, Du X, Fu Q, Peng W, et al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study. HIV Med 2018;19 (Suppl. 3).
21.Yue Y, Wang N, Han Y, Zhu T, Xie J, Qiu Z, et al. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV–1 DNA level in chronically infected patients on antiretroviral therapy: a case control study. BMC Infect Dis 2017;17: 771.
22.Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV–1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 2014;59: 1312–21.
23.Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, et al. Long-term antiretroviral therapy initiated during primary HIV–1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013;68: 1169–78.
24.Luo L, Wang N, Yue Y, Han Y, Lv W, Liu Z, et al. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study. BMC Infect Dis 2019;19: 257.
25.Lu Z, Jiao Y, Li J, Lan G, Lu C, Li X, et al. After 18 months of antiretroviral therapy, total HIV DNA decreases more pronouncedly in patients infected by CRF01_AE than in those infected by subtype B and CRF07_BC. Microbiol Immunol 2018;62: 248–54.
26.Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV–1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 2014;210: 728–35.
27.Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The Depsipeptide Romidepsin Reverses HIV–1 Latency In Vivo. PLoS Pathog 2015;11: e1005142.
28.Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV–1-infected adults on antiretroviral therapy[J]. Clin Infect Dis 2014;58: 883–90.
29.Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV–1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9: e1003211.
30.Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV–1 DNA predicts disease progression and post-treatment virological control. Elife 2014;3: e03821.
31.Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al. Early levels of HIV–1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV–1 RNA levels and CD4+ T cell counts. J Infect Dis 2005;192: 46–55.
32.Zhang H, Jiao Y, Li H, Zhu W, Li W, Huang X, et al. Longitudinal changes in total, 2-LTR circular, and integrated HIV–1 DNA during the first year of HIV–1 infection in CD4Low and CD4High patient groups with HIV–1 subtype AE. Viral Immunol 2014;27: 478–82.
33.Chow WZ, Lim SH, Ong LY, Yong YK, Takebe Y, Kamarulzaman A, et al. Impact of HIV–1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients. PLoS One 2015;10: e0137281.
34.Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208: 1202–11.
35.Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, et al. Long-term antiretroviral treatment initiated at primary HIV–1 infection affects the size, composition, and decay kinetics of the reservoir of HIV–1-infected CD4 T cells. J Virol 2014;88: 10056–65.
36. Chu M, Zhang W, Zhang X, Jiang W, Huan X, Meng X, et al. HIV–1 CRF01_AE strain is associated with faster HIV/AIDS progression in Jiangsu Province, China. Sci Rep 2017;7: 1570.
37.Oyomopito RA, Li PC, Sungkanuparph S, Phanuphak P, Tee KK, Sirisanthana T, et al. Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV–1 CRF01_AE and subtype B. J Acquir Immune Defic Syndr 2013;62: 293–300.
38.Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N. Do HIV–1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. J Int AIDS Soc 2014;17: 18944.